fasedienol

Small molecule

Negativelead readout

Evidence outlook · lead readout

Palisade-1 (NCT04754802) · Social Anxiety Disorder

The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.

Palisade-1 (NCT04754802): The trial was randomized, triple-blind, placebo-controlled, and included 224 participants, with a clinical symptom measure (SUDS) as the primary endpoint. The primary comparison was not statistically significant: mean SUDS at Visit 3 was 62.3 with fasedienol versus 61.3 with placebo (p=0.5063; 95% CI for the difference, -3.2 to 6.4), so the findings provide well-designed but unclear evidence of benefit.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Social Anxiety Disorder
NCT05030350 · VistaGen Therapeutics, Inc.
2021-10-01 – 2022-09-23 · Social Anxiety Disorder
What this study did
NCT05011396 · VistaGen Therapeutics, Inc.
2021-08-30 – 2022-08-16 · Social Anxiety Disorder
What this study did
NCT02622958 · Pherin Pharmaceuticals, Inc.
2014-03 – 2015-03 · Social Anxiety Disorder
What this study did
Phase 2 (3)
Social Anxiety Disorder
NCT06809179 · VistaGen Therapeutics, Inc.
2025-01-09 – 2026-08-26 · Social Anxiety Disorder
What this study did
NCT01217788 · Pherin Pharmaceuticals, Inc.
2008-02 – 2011-03 · Social Phobia, Social Anxiety Disorder
What this study did
Other / comorbidity
NCT04404192 · VistaGen Therapeutics, Inc.
2021-10-12 – 2022-12-14 · Adjustment Disorder With Anxious Mood
What this study did

Competitive landscape

This drug's own stage for Social Anxiety Disorder: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fasedienol: this drugPhase 3Small moleculeNasal chemosensory receptorsPartial signal
NCT04754802: Subjective Units of Distress Scale (SUDS) Score (Visit 2 (Baseline; Day 0) to Visit 3 (Day 7 ± 2 days)): PH94B — Visit 2: 77.7 score on a scale (Standard Deviation 11.67); Visit 3: 62.3 score on a scale (Standard Deviation 19.4) | Placebo — Visit 2: 78.2 score on a scale (Standard Deviation 12.42); Visit 3: 61.3 score on a scale (Standard Deviation 19.56) missed
EMP-01Phase 2Small moleculeSerotonergic system (MDMA-class entactogen)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 August 2026Topline resultExploratory Phase 2 repeat-dose study of fasedienol: primary endpoint not statistically significant
VistaGen Therapeutics · Source ↗
30 June 2026Topline resultPhase 3 PALISADE-4 of fasedienol did not meet its primary endpoint
VistaGen Therapeutics · Source ↗
June 2026Topline resultPALISADE-4 randomized portion missed primary endpoint